Galectin-3, osteopontin and successful aging

Abstract

Individuals who reach exceptional longevity (100+ years of age) free of common chronic age diseases (i.e. ‘dodgers’) arguably represent the paradigm of successful aging in humans. As such, identification of potential biomarkers associated with this phenomenon is of medical interest. We measured serum levels of galectin-3 and osteopontin, both of which have been shown to be linked with major chronic or aging-related disorders in younger populations, in centenarian ‘dodgers’ (n=81; 40 men; 100–104 years) and healthy controls (n=41; 24 men, 70–80 years). Lower levels of both galectin-3 and osteopontin are associated with successful aging, representing potential biomarkers of this condition. Our cross-sectional data must be however approached with caution. Further research is necessary to replicate the present preliminary results in other cohorts and to identify the potential use of galectin-3 and osteopontin as potential targets (or at least predictors) in future personalized anti-aging therapies.